Prospective digital neurocognitive and patient-reported symptom monitoring in adults scheduled for CAR T-cell therapy: feasibility and exploratory patient-level observations from a single-center cohort

Purpose To evaluate completion of individually tailored digital neurocognitive and symptom assessments in adults scheduled for CAR T-cell therapy and explore longitudinal changes in task-specific outcomes. Methods In this prospective single-center cohort (n = 33), NeuroCAT comprised 25 cognitive, visual, and graphomotor tasks and a symptom questionnaire at baseline (T0). At early post-infusion (T1) and pre-discharge (T2), investigators selected approximately eight tasks per participant. Results All 33 patients completed T0, and 30 (90.9%; Wilson 95% confidence interval, 76.4–96.9%) completed both T1 and T2 assessments. Two patients died before follow-up, and one did not undergo follow-up after interruption of the planned treatment pathway due to clinical instability. Paired quantitative T0/T2 observations were available for only 4-11 patients per task, with heterogeneous changes in task-specific indices and patient-reported symptoms. Among three patients with chart-documented grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS), one had increased fatigue and neuropathic pain ratings and another had increased dizziness and concentration-difficulty ratings. Nonspecific symptom worsening was also observed in patients without ICANS. Conclusion Completion of individually assigned follow-up assessments was high among enrolled patients. Nonrandom task selection, limited paired observations, unvalidated task indices, and nonspecific symptom changes preclude conclusions about ICANS detection or clinical utility. Prospective validation is required. Relevance to supportive care Tailored digital assessments may support structured symptom documentation during CAR T-cell therapy, but patient burden and clinical value remain to be established.

Authors

Publication Details

Journal
Supportive Care in Cancer
Published
2026-11-20
DOI
https://doi.org/10.1007/s00520-026-11493-1
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prospective digital neurocognitive and patient-reported symptom monitoring in adults scheduled for CAR T-cell therapy: feasibility and exploratory patient-level observations from a single-center cohort

Anna Fleischer, Imad Maatouk, Johannes Schobel, Sophia Danhof et al.
Supportive Care in Cancer
CAR-T cell therapy research
article

Prospective digital neurocognitive and patient-reported symptom monitoring in adults scheduled for CAR T-cell therapy: feasibility and exploratory patient-level observations from a single-center cohort

Anna Fleischer, Imad Maatouk, Johannes Schobel, Sophia Danhof, Jessica Peter, Carmen Sanges, Götz Gelbrich, Thomas Däullary, Patrick‐Pascal Strunz, Julia Mersi, Michael Hudecek, Johannes Düll, Barbara Huber, Eleni Kakavela, Hermann Einsele, Johannes Waldschmidt, K. Martin Kortüm, Christofer Pohl, Leo RASCHE, Max Topp, Luna Dressler, Onur Duman
article en

Abstract

Purpose To evaluate completion of individually tailored digital neurocognitive and symptom assessments in adults scheduled for CAR T-cell therapy and explore longitudinal changes in task-specific outcomes. Methods In this prospective single-center cohort (n = 33), NeuroCAT comprised 25 cognitive, visual, and graphomotor tasks and a symptom questionnaire at baseline (T0). At early post-infusion (T1) and pre-discharge (T2), investigators selected approximately eight tasks per participant. Results All 33 patients completed T0, and 30 (90.9%; Wilson 95% confidence interval, 76.4–96.9%) completed both T1 and T2 assessments. Two patients died before follow-up, and one did not undergo follow-up after interruption of the planned treatment pathway due to clinical instability. Paired quantitative T0/T2 observations were available for only 4-11 patients per task, with heterogeneous changes in task-specific indices and patient-reported symptoms. Among three patients with chart-documented grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS), one had increased fatigue and neuropathic pain ratings and another had increased dizziness and concentration-difficulty ratings. Nonspecific symptom worsening was also observed in patients without ICANS. Conclusion Completion of individually assigned follow-up assessments was high among enrolled patients. Nonrandom task selection, limited paired observations, unvalidated task indices, and nonspecific symptom changes preclude conclusions about ICANS detection or clinical utility. Prospective validation is required. Relevance to supportive care Tailored digital assessments may support structured symptom documentation during CAR T-cell therapy, but patient burden and clinical value remain to be established.

Supportive Care in CancerVol. 34(12)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon